Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
Protagonist Therapeutics revenue
Protagonist Therapeutics's revenue is $434.4 million.
What is Protagonist Therapeutics's revenue?
- Protagonist Therapeutics's revenue growth from 2017 to 2024 is 2,065.34%.
- Protagonist Therapeutics has 118 employees, and the revenue per employee ratio is $3,681,635.
- Protagonist Therapeutics's peak quarterly revenue was $255.0M in 2024(q1).
- Protagonist Therapeutics peak revenue was $434.4M in 2024.
- Protagonist Therapeutics annual revenue for 2023 was 60.0M, 125.73% growth from 2022.
- Protagonist Therapeutics annual revenue for 2024 was 434.4M, 624.05% growth from 2023.
On this page
Zippi applies for you, and finds you a job.
Protagonist Therapeutics historical revenue
Protagonist Therapeutics's peak revenue was $434.4M in 2024. The peak quarterly revenue was $255.0M in 2024(q1).
Protagonist Therapeutics's revenue increased from $20.1m in 2017 to $434.4M currently. That's a 2,065.34% change in annual revenue.
Protagonist Therapeutics annual revenue
Protagonist Therapeutics annual revenue over time
| Fiscal year / year | Protagonist Therapeutics revenue |
|---|---|
| 2017 | $20.1M |
| 2018 | $30.9M |
| 2019 | $231,000 |
| 2020 | $28.6M |
| 2021 | $27.4M |
| 2022 | $26.6M |
| 2023 | $60.0M |
| 2024 | $434.4M |
How accurately did Protagonist Therapeutics' revenue projections match actual performance?
Protagonist Therapeutics annual growth
Protagonist Therapeutics saw the greatest revenue growth in 2020, when revenue increased by 12,293.07%.
Protagonist Therapeutics had the lowest revenue growth in 2019, when revenue changed by -99.25%.
Protagonist Therapeutics annual growth rate over time
| Year | Protagonist Therapeutics growth |
|---|---|
| 2018 | 54%↑ |
| 2019 | -99%↓ |
| 2020 | 12293%↑ |
| 2021 | -4%↓ |
| 2022 | -3%↓ |
| 2023 | 126%↑ |
| 2024 | 624%↑ |
Protagonist Therapeutics quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
Protagonist Therapeutics quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2017 | - | - | $8.8M | $11.3M |
| 2018 | $10.8M | $11.7M | $6.1M | $2.4M |
| 2019 | $1.6M | ($8.2M) | $4.1M | $2.7M |
| 2020 | $3.6M | $6.2M | $13.1M | $5.7M |
| 2021 | $6.2M | $2.3M | $10.3M | $8.6M |
| 2022 | $25.7M | $859,000 | - | - |
| 2023 | - | - | - | $59.9M |
| 2024 | $255.0M | $4.2M | $4.7M | $170.6M |
Protagonist Therapeutics jobs nearby
Do you work at Protagonist Therapeutics?
Did Protagonist Therapeutics meet its revenue projections?
Protagonist Therapeutics financial information
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 118 |
| Date Founded | 2006 |
| Headquarters | Newark, California |
| Number of Locations | 1 |
| Revenue | $434.4M |
| Net Income | -$127,393,000 |
| Tax Rate | 0.0% |
| Total Assets | $247,928,000 |
| Ticker | PTGX |
Protagonist Therapeutics jobs you might like
Protagonist Therapeutics financing
Protagonist Therapeutics received early financing of $18.0M on 2013-06-11.
| Series | Round size | Date |
|---|---|---|
| Equity | $40M | 07/2015 |
| Equity | $18M | 06/2013 |
Protagonist Therapeutics investors
| Investors | Security type |
|---|---|
| National Institutes of Health | Grant - Protagonist Therapeutics |
| National Institutes of Health | Grant - Protagonist Therapeutics |
| Adage Capital Management | Series C - Protagonist Therapeutics |
| Canaan Partners | Series C - Protagonist Therapeutics |
| RA Capital Management | Series C - Protagonist Therapeutics |
| Inbio Ventures | Series C - Protagonist Therapeutics |
| Foresite Capital | Series C - Protagonist Therapeutics |
| Pharmstandard | Series B - Protagonist Therapeutics |
| Johnson & Johnson Development Corporation | Series B - Protagonist Therapeutics |
| Inbio Ventures | Series B - Protagonist Therapeutics |
Protagonist Therapeutics competitors
Protagonist Therapeutics's top competitor, Kiniksa Pharmaceuticals, earned an annual revenue of $423.2M.
Protagonist Therapeutics's smallest competitor is Onconova Therapeutics with revenue of $226.0K last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Omeros | - | $29.9M | 265 | - |
| Kiniksa Pharmaceuticals | - | $423.2M | 111 | - |
| Ophthotech | - | $210.0M | 58 | - |
| Palatin Technologies | - | $4.9M | 18 | - |
| Bellicum Pharmaceuticals | - | $1.5M | 16 | - |
| Onconova Therapeutics | - | $226,000 | 12 | - |
| Aclaris Therapeutics | - | $18.7M | 60 | - |
| InMed Pharmaceuticals | - | $1.6M | 20 | - |
| Lankenau Institute for Medical Research | - | $8.9M | 125 | - |
| Crown Bioscience | - | $12.0M | 350 | - |
Protagonist Therapeutics revenue FAQs
Search for jobs
Related company revenues
Working at related companies
Related company jobs
Most in demand jobs
Zippia gives an in-depth look into the details of Protagonist Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Protagonist Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at Protagonist Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Protagonist Therapeutics. The data presented on this page does not represent the view of Protagonist Therapeutics and its employees or that of Zippia.
Protagonist Therapeutics may also be known as or be related to PROTAGONIST THERAPEUTICS INC, Protagonist Therapeutics, Protagonist Therapeutics Inc, Protagonist Therapeutics, Inc and Protagonist Therapeutics, Inc.